Nanomaterials in targeting amyloid-β oligomers: current advances and future directions for Alzheimer's disease diagnosis and therapy

• Shiwani Randhawa,
• Trilok Chand Saini,
• Manik Bathla,
• Rahul Bhardwaj,
• Rubina Dhiman and
• Amitabha Acharya

Beilstein J. Nanotechnol. 2025, 16, 561–580, doi:10.3762/bjnano.16.44

Biomimetic nanocarriers: integrating natural functions for advanced therapeutic applications

• Hugo Felix Perini,
• Beatriz Sodré Matos,
• Carlo José Freire de Oliveira and
• Marcos Vinicius da Silva

Beilstein J. Nanotechnol. 2024, 15, 1619–1626, doi:10.3762/bjnano.15.127

• targeting specificity. Biomimetic nanocarriers demonstrate significant advancements in drug delivery systems against cancer therapy, Alzheimer's disease, autoimmune diseases, and viral infections such as COVID-19. Here, we address the therapeutic applications of biomimetic nanocarriers and their promising

• employed in treating other diseases, such as Alzheimer's disease. Current medications for Alzheimer's face the challenge of the blood–brain barrier (BBB), which includes the blood–brain, cerebrospinal fluid–brain, and blood–cerebrospinal fluid barriers. These barriers exhibit high selectivity in drug

• nonpermissive characteristics at the barrier [69]. Polymeric nanoparticles, as well as those based on lipids and inorganic materials, are extensively studied for Alzheimer's disease treatment due to their tissue selectivity, potential circulation time, encapsulation capacity, and, importantly, their ability to

Fabrication of nanocrystal forms of ᴅ-cycloserine and their application for transdermal and enteric drug delivery systems

• Hsuan-Ang Tsai,
• Tsai-Miao Shih,
• Theodore Tsai,
• Jhe-Wei Hu,
• Yi-An Lai,
• Jui-Fu Hsiao and
• Guochuan Emil Tsai

Beilstein J. Nanotechnol. 2024, 15, 465–474, doi:10.3762/bjnano.15.42

• studied over the last three decades, primarily due to its centrally active partial agonism of N-methyl-ᴅ-aspartate (NMDA) receptor [3][4][5][6][7][8][9][10][11][12]. Several researches indicated that DCS is a potential drug candidate to treat CNS disorders such as depression, schizophrenia, Alzheimer's

• disease, and post-traumatic stress disorder [13][14][15][16]. In general, solid dosage forms for oral administration are preferable for therapies against CNS disorders. Nevertheless, challenges persist with oral solid dosage forms, including issues of bioavailability and clinical efficacy [17]. On the

Ultrasensitive detection of cadmium ions using a microcantilever-based piezoresistive sensor for groundwater

• Dinesh Rotake,
• Anand Darji and
• Nitin Kale

Beilstein J. Nanotechnol. 2020, 11, 1242–1253, doi:10.3762/bjnano.11.108

• degeneration, diarrhea, osteoporosis, renal dysfunction, cancer, anemia, and neurological disorders such as Parkinson's disease or Alzheimer's disease [4][5]. The WHO has set a water contamination limit of 3 μg/L Cd(II) [6]. We conclude from the WHO limit that cadmium is hazardous, and smaller Cd

Strategy to discover full-length amyloid-beta peptide ligands using high-efficiency microarray technology

• Clelia Galati,
• Natalia Spinella,
• Lucio Renna,
• Danilo Milardi,
• Francesco Attanasio,
• Michele Francesco Maria Sciacca and
• Corrado Bongiorno

Beilstein J. Nanotechnol. 2017, 8, 2446–2453, doi:10.3762/bjnano.8.243

• well as the low sample consumption and the high potential for miniaturization, suggests that the proposed combination of peptide microarrays and highly efficient slides would be a very effective technology for molecule profiling in AD drug discovery. Keywords: Alzheimer's disease; florescence; high

Carbon nano-onions as fluorescent on/off modulated nanoprobes for diagnostics

• Stefania Lettieri,
• Marta d’Amora,
• Adalberto Camisasca,
• Alberto Diaspro and
• Silvia Giordani

Beilstein J. Nanotechnol. 2017, 8, 1878–1888, doi:10.3762/bjnano.8.188

• changes in the cells and tissues. Some of these events include cell proliferation and apoptosis [1], ion transport [2] and other cellular process and diseases such as cancer [3][4][5], Parkinson's, and Alzheimer's disease [6]. Despite the large number of nanotechnology platforms available to date for

Unraveling the neurotoxicity of titanium dioxide nanoparticles: focusing on molecular mechanisms

• Bin Song,
• Yanli Zhang,
• Jia Liu,
• Xiaoli Feng,
• Ting Zhou and
• Longquan Shao

Beilstein J. Nanotechnol. 2016, 7, 645–654, doi:10.3762/bjnano.7.57

• disorders with remarkable excitatory toxicity elements. Furthermore, the transcription of EAAT2 could be recovered by suppression of DNA methyltransferases [90]. Neurodegenerative diseases, such as Alzheimer's disease (AD) [91], Huntington’s disease (HD) [92], and amyotrophic lateral sclerosis (ALS) [93